Table 4.
CAR-T cell therapy trials for breast cancer in the recruitment phase
| Agents | Trial / Phase | Setting |
|---|---|---|
| CAR T cells recognizing EpCAM | EpCAM CAR-T for Treatment of Nasopharyngeal Carcinoma and Breast Cancer / Phase 1 | Adjuvant/ metastatic |
| Chimeric antigen receptor T-cell therapy | HER2-CAR T Cells in Treating Patients with Recurrent Brain or Leptomeningeal Metastases / Phase 1 | Metastatic |
| Cyclophosphamide mesothelin-targeted T cells AP1903 | T-Cell Therapy for Advanced Breast Cancer / Phase 1 | Metastatic |
| CEA CAR T cells | Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer / Phases 1 and 2 | Metastatic |
| Cyclophosphamide Fludarabine Aldesleukin Anti-hCD70 CAR-transduced PBL |
Administering Peripheral Blood Lymphocytes Transduced with a CD70-Binding Chimeric Antigen Receptor to People with CD70 Expressing Cancers / Phases 1 and 2 | Metastatic |
| huMNC2-CAR44 CAR T cells | Autologous huMNC2-CAR44 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*) / Phase 1 | Metastatic |
| C7R-GD2.CART cells Cyclophosphamide Fludarabine | C7R-GD2.CART Cells for Patients with Relapsed or Refractory Neuroblastoma and Other GD2-Positive Cancers (GAIL-N) / Phase 1 | Metastatic |